Unconventional pattern of response in a metastatic melanoma patient treated with ipilimumab

Francesco Spagnolo, Serena Savaia, Marco Grosso, Paola Queirolo

Research output: Contribution to journalArticlepeer-review


We present the case of a 74 year old man who achieved a complete response for hepatic and cutaneous metastasis and stabilization of his lymph node metastases after treatment with ipilimumab at 10 mg/Kg. The patient was diagnosed with right foot cutaneous melanoma in February 2004. In October the patient became metastatic and he underwent three different lines of tradi-tional chemotherapy (Fotemustine, Dacarbazin and Carboplatin with Thalidomide) but each time a progression of the disease was noted. Consequently, the patient was enrolled in Protocol CA180008 and treated with ipilimumab 10mg/Kg every 3 weeks for 4 cycles. Ipilimumab has been established as a drug able to induce long-lasting responses, and has been approved for patients with metastatic melanoma in first- and second-line treatment by the FDA and in second-line treatment by the EMA.

Original languageEnglish
Pages (from-to)72-74
Number of pages3
JournalEuroMediterranean Biomedical Journal
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Unconventional pattern of response in a metastatic melanoma patient treated with ipilimumab'. Together they form a unique fingerprint.

Cite this